Alexandria Venture Investments

Eikon Therapeutics

Millbrae

Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.

insitro

South San Francisco

Insitro is a drug discovery and development startup that utilizes machine learning and biology to transform drug discovery.

Neurona Therapeutics

South San Francisco

Neurona Therapeutics is a biotherapeutics company that focuses on developing cell-based therapies to address neurological disorders.

Stoke Therapeutics

Bedford

Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.

Ring Therapeutics

Cambridge

Ring Therapeutics is a gene therapy company focused on discovering and developing programmable genetic medicines.

Proxima

New York

Proxima Bio develops programmable medicines that modulate protein interactions to address disease processes.

HAYA Therapeutics

Lausanne

HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome.

Nitrase Therapeutics

Brisbane

Nitrase Therapeutics is developing drugs against newly discovered nitration enzyme(s).

Xilis

Durham

Xilis is an oncology and precision health company that provides technologies to diagnoses cancer.

AltPep

Seattle

AltPep provides a novel approach for tackling amyloid diseases, with diagnostic, therapeutic and anti-biofilm applications.

Aitia

Cambridge

Leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs

Immunai

New York

The company maps and decodes the immune system using single-cell biology and AI, aiming to power therapeutic discoveries and accelerate drug development. By translating complex immune data into actionable insights, it seeks to improve patie

Affini-T Therapeutics

Watertown

Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer.

Lycia Therapeutics

South San Francisco

Lycia is a Series B biotech company built on a platform developed by academic founder Professor Carolyn Bertozzi at Stanford, arising from Stanford research, with potential to deliver next-generation therapeutics for difficult-to-treat dise